Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jan 18;15(3):e00682. doi: 10.14309/ctg.0000000000000682

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PMC Copyright notice

Figure 6. — Loss of NRIP3 expression sensitized cells to NVP-BEZ235/VE-822 and NVP-BEZ235/AZD0156. (a) The IC50 curve of VE-822 and AZD0156 under cisplatin treatment in CRC cells. (b) The levels of ATR, p-ATR, ATM, p-ATM, CHK1, p-CHK1, CHK2, and p-CHK2 in NRIP3 unexpressed and reexpressed CRC cells with or without cisplatin treatment (0.1 μM). (c) MTT assay shows the sensitivity of CRC cells to VE-822, AZD0156, or NVP-BEZ235. VE-822: 0.2 μM; AZD0156: 0.5 μM; NVP-BEZ235: 50 nM. VE-822 + NVP-BEZ235: VE-822 plus NVP-BEZ235 treatment; AZD0156 + NVP-BEZ235: AZD0156 plus NVP-BEZ235 treatment. *P < 0.05, ***P < 0.001.